NCT04338646

Brief Summary

Falls are a common problem in people with multiple sclerosis (PwMS) and can lead to severe consequences (trauma, fear of falling, reduction of social activities). Prevention of falls is one of the priority targets of rehabilitation for PwMS and walking difficulties, which can result of different factors (motor impairment, ataxia, sensitive disorders, fatigability…). Urinary incontinence has been evoked as predictive of falls. But lower urinary tract symptoms (LUTSs) are frequent in PwMS, the prevalence of LUTSs is high (32-96.8%) and increases with MS duration and severity of neurological deficiencies and disabilities. Overactive bladder (OAB) is the most common symptom. Despite its high prevalence and impact on quality of life, the severity of LUTSs has never been studied as specific risk factor of falling. However, urinary urgency and urinary incontinence could lead to precipitation and thus could increase the risk of falling in these patients. The aim of the study was to assess the relationship between severity of LUTSs and risk of falling in PwMS. Patients were asked about the number of falls in the past three months and in the past year, and the circumstances in which they occurred (frequency, home, outdoors, going to void, during urinary urgency, nocturia). Severity of LUTSs were assessed by the Urinary Symptoms Profile (USP) Score and patient were classified as with or without urinary incontinence. Number of micturition by night were specifically asked. To take into account motor difficulties and fear of falling, other clinical evaluations were done. The impact of MS on walking was assessed by the 12-Item Multiple Sclerosis Walking Scale (MSWS12) questionnaire, the Expanded Disability Status Scale score, and by clinical test with the Time to be Ready to Void (TRV). Fear of falling was assessed by a simple question and with Falls Efficacy Scale-International (FES-I) Questionnaire. The primary aim was to assess the relationship between severity of LUTSs and occurrence of falls during the past 3 months. The primary outcome was the importance of overactive bladder (OAB) symptoms with OAB USP score. The secondary outcomes were the existence of urinary incontinence, the warning time (defined as the time from the first sensation of urgency to voiding or incontinence), the importance of nocturia and the other scores of USP questionnaire (low stream and stress urinary incontinence). The secondary aims were to look for the relationship between severity of LUTSs and occurrence of falls during the past year, and to assess the relationship between falls and the classical risk factors of falls.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jul 2019

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2019

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

April 4, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 8, 2020

Completed
7 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 15, 2020

Completed
15 days until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2020

Completed
Last Updated

February 18, 2022

Status Verified

February 1, 2022

Enrollment Period

10 months

First QC Date

April 4, 2020

Last Update Submit

February 17, 2022

Conditions

Keywords

Fallmultiple sclerosislower urinary tract symptomsoveractive bladder

Outcome Measures

Primary Outcomes (1)

  • Number of falls in the past 3 months

    Patients were asked about the number of falls in the past three months, and the circumstances in which they occurred (frequency, home, outdoors, going to void, during urinary urgency, nocturia)

    1 day

Secondary Outcomes (1)

  • Number of falls in the past year

    1 day

Other Outcomes (1)

  • Correlation between number of falls in the past 3 months and in the past year and clinical datas and characteristics of the patient

    1 day

Study Arms (1)

Patients enrolled

Patient with multiple sclerosis and lower urinary tract symptoms, age \>18 Expanded Disability Status Scale score between 1 and 6.5

Other: Clinical tests

Interventions

Questionnaire about urinary symptoms, gait difficulties, fear of falling. Clinical test: Time to be Ready to Void

Patients enrolled

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients consulting in a tertiary center in neuro-urology

You may qualify if:

  • age ≥ 18 years
  • Multiple sclerosis (MS) diagnosis
  • Lower urinary tract symptoms with or without treatment,
  • Expanded Disability Status Scale score between 1 and 6.5

You may not qualify if:

  • relapse of MS in the past month
  • impossibility to complete the symptoms' questionnaires

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

department of Neuro-Urology, Hôpital Tenon

Paris, 75020, France

Location

Related Publications (1)

  • Hentzen C, Villaume A, Turmel N, Chesnel C, Le Breton F, Haddad R, Amarenco G. Are falls in people with multiple sclerosis related to the severity of urinary disorders? Ann Phys Rehabil Med. 2021 Jul;64(4):101452. doi: 10.1016/j.rehab.2020.10.006. Epub 2020 Dec 5.

MeSH Terms

Conditions

Multiple SclerosisLower Urinary Tract SymptomsUrinary Bladder, Overactive

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System DiseasesUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsUrinary Bladder DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Study Officials

  • Gérard Amarenco, PhD

    Sorbonne Université, GRC 001, GREEN, AP-HP, Hôpital Tenon, Paris, France

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Head of Neuro-Urology department, Tenon Hospital

Study Record Dates

First Submitted

April 4, 2020

First Posted

April 8, 2020

Study Start

July 1, 2019

Primary Completion

April 15, 2020

Study Completion

April 30, 2020

Last Updated

February 18, 2022

Record last verified: 2022-02

Locations